Morphological and ophthalmoscopic features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy

Abstract

Although methods are available to treat proliferative diabetic retinopathy (PDR), 30% of cases progress, which is an indication for vitrectomy. Purpose: To investigate the ophthalmoscopic and morphological features of epiretinal membranes (ERMs) in patients with PDR depending on the dose of preoperative intravitreal aflibercept (PIA). Material and Methods: Seventy-five patients (75 eyes) with PDR and the presence of fibrovascular ERM with a marked proliferative component were involved in the study. Patients were divided into three groups: eyes of group 1 or control group (31 eyes) received vitrectomy without PIA; group 2 (17 eyes), PIA 1.0 mg; and group 3 (27 eyes), PIA 2.0 mg. We performed a histological study on specimens of fibrovascular ERMs surgically obtained from patients to determine the microscopic features of these membranes. Results: There was ophthalmoscopic and microscopic evidence that aflibercept pretreatment in vitrectomy for PDR resulted in fibrosis of the ERM. The extent of fibrosis of the ERM and obliteration of newly formed blood vessels in the ERM depended on the dose of PIA. Complete obliteration of newly formed blood vessels in the ERM was observed as early as day 3 after 2.0-mg intravitreal aflibercept injection compared to day 5 after 1.0-mg intravitreal aflibercept injection. Pretreatment with 1.0-mg intravitreal aflibercept in vitrectomy for PDR reduced the probability of complications associated with ERM contraction, worsening of the tractional component and the development of a retinal break.

Concentration of Vascular Endothelial Growth Factor in the Vitreous and Features of Vitrectomy in Patients with Proliferative Diabetic Retinopathy after Various Doses of Intravitreal Aflibercept

“…Афлиберсепт, в отличие от других препаратов ингибиторов ФРЭС, связывает не только все изоформы ФРЭС-A, но и плацентарный фактор роста, и ФРЭС-В [14]. В наших предварительных исследованиях было установлено, что интравитреальное введение афлиберсепта в дозировке 1 и 2 мг приводит к фибротизации фиброваскулярных ЭРМ с выраженным пролиферативным компонентом и облитерации новообразованных сосудов на 3-и и 5-е сутки после инъекции, однако уровень ФРЭС в стекловидном теле и особенности витрэктомии при этом не изучались [18,19].…”